Showing results (251-260 of 993) with videos related to

Sort By:
Pageof 100
British Journal of Cancer|October 29, 2002
Regulation of a rat VL30 element in human breast cancer cells in hypoxia and anoxia: role of HIF-1K Ameri, B Burke, C E Lewis, et al.
Cancer Research|April 1, 1990
Correlation of enhanced 6-mercaptopurine cytotoxicity with increased phosphoribosylpyrophosphate levels in Chinese hamster ovary cells treated with 3-aminobenzamideK Moses, E Willmore, A L Harris, et al.
Oncogene|June 27, 2006
Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancerA L Bacon, S Fox, H Turley, et al.
Biochemical and Biophysical Research Communications|November 21, 1997
Expression of Wnt5a is downregulated by extracellular matrix and mutated c-Ha-ras in the human mammary epithelial cell line MCF-10AT D Bui, G Tortora, F Ciardiello, et al.
Journal of Undergraduate Neuroscience Education : JUNE : a Publication of FUN, Faculty for Undergraduate Neuroscience|July 31, 2019
Development of an Introductory Neuroscience Teaching Experience for Undergraduates with a Low-Cost Neuroscience Summer AcademyK N Colpitts, K P Seymour, A L Harris Bozer
Journal of Cell Science|August 1, 1995
Inactivation of Cdc2 increases the level of apoptosis induced by DNA damageW Ongkeko, D J Ferguson, A L Harris, et al.
Anticancer Research|July 1, 1996
Relationship between topoisomerase II levels and resistance to topoisomerase II inhibitors in lung cancer cell linesS Houlbrook, A L Harris, J Carmichael, et al.
Hormone Research|January 1, 1989
Zoladex: therapeutic effects in postmenopausal breast cancerA L Harris, J Carmichael, B M Cantwell, et al.
British Journal of Cancer|October 1, 1983
Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancerA L Harris, M Dowsett, I E Smith, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant diseaseJ Carmichael, P A Philip, C Forfar, et al.
Pageof 100